Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers found that the more people with HIV drank, the lower a biomarker of bone formation.
Switching to new tenofovir tied to improved bone health in older people with HIV
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Participants entered the study taking tenofovir disoproxil fumarate, and some were switched to a regimen including tenofovir alafenamide.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.
Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.
With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.